Synaptogenix, Inc. filed a Form D with the Securities and Exchange Commission on 2025-06-23.
Synaptogenix, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 23, 2025. The filing reports $5.50M sold. Its industry group is Biotechnology. It names ROBERT WEINSTEIN (CHIEF FINANCIAL OFFICER), JOSHUA SILVERMAN (EXECUTIVE CHAIRMAN), WILLIAM SINGER (Director) (SEC Form D, June 23, 2025).
Is this your company?
Sell to companies like Synaptogenix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-06-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Synaptogenix, Inc.
Free to see. No signup.
More on the people and the money behind Synaptogenix, Inc., from the filings we hold.
Biotechnology raises by companies based in New York, filed within 90 days of this one, largest first.
Get an email when Synaptogenix, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Synaptogenix, Inc. raises, hires or launches. No email unless you switch it on.
Watch Synaptogenix, Inc. →Get the full cited report on Synaptogenix, Inc.
What the filing shows about Synaptogenix, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Synaptogenix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Synaptogenix, Inc.'s address as 1185 Avenue Of The Americas, 3RD Floor, New York, NY 10036.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Synaptogenix, Inc. is a registered filer with the SEC (CIK 1571934) and has filed since 2024-09-23. 3 filings are on record, the latest on 2025-10-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Synaptogenix, Inc.'s Form D of 2025-06-23 names ROBERT WEINSTEIN, JOSHUA SILVERMAN, WILLIAM SINGER and 2 more as its officers, directors or promoters.
Its new offerings report $19.71M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
On the filing as: Executive Officer.
Robert Weinstein is named as Chief Financial Officer on the Form D that Synaptogenix, Inc. filed with the SEC on 23 June 2025, one of 5 people that filing names.
On the filing as: Executive Officer, Director.
Joshua Silverman is named as Executive Chairman on the Form D that Synaptogenix, Inc. filed with the SEC on 23 June 2025, one of 5 people that filing names.
William Singer is named as Director on the Form D that Synaptogenix, Inc. filed with the SEC on 23 June 2025, one of 5 people that filing names.
Bruce Bernstein is named as Director on the Form D that Synaptogenix, Inc. filed with the SEC on 23 June 2025, one of 5 people that filing names.
Jonathan Schechter is named as Director on the Form D that Synaptogenix, Inc. filed with the SEC on 23 June 2025, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2025-06-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Synaptogenix, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Synaptogenix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Synaptogenix, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Synaptogenix, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Synaptogenix, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Synaptogenix, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in New York
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/synaptogenix-inc-form-d-25000001